Understanding Neuromuscular Health and Disease: Advances in Genetics, Omics, and Molecular Function

This compilation focuses on recent advances in the molecular and cellular understandingof neuromuscular biology, and the treatment of neuromuscular disease.These advances are at the forefront of modern molecular methodologies, oftenintegrating across wet-lab cell and tissue models, dry-lab computati...

Full description

Saved in:
Bibliographic Details
Other Authors: Duddy, William (Editor), Duguez, Stephanie (Editor)
Format: Electronic Book Chapter
Language:English
Published: Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2021
Subjects:
ALS
MND
SNP
AAV
SMA
DMD
n/a
Online Access:DOAB: download the publication
DOAB: description of the publication
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000naaaa2200000uu 4500
001 doab_20_500_12854_76949
005 20220111
003 oapen
006 m o d
007 cr|mn|---annan
008 20220111s2021 xx |||||o ||| 0|eng d
020 |a books978-3-0365-1621-9 
020 |a 9783036516226 
020 |a 9783036516219 
040 |a oapen  |c oapen 
024 7 |a 10.3390/books978-3-0365-1621-9  |c doi 
041 0 |a eng 
042 |a dc 
072 7 |a GP  |2 bicssc 
100 1 |a Duddy, William  |4 edt 
700 1 |a Duguez, Stephanie  |4 edt 
700 1 |a Duddy, William  |4 oth 
700 1 |a Duguez, Stephanie  |4 oth 
245 1 0 |a Understanding Neuromuscular Health and Disease: Advances in Genetics, Omics, and Molecular Function 
260 |a Basel, Switzerland  |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2021 
300 |a 1 electronic resource (318 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
506 0 |a Open Access  |2 star  |f Unrestricted online access 
520 |a This compilation focuses on recent advances in the molecular and cellular understandingof neuromuscular biology, and the treatment of neuromuscular disease.These advances are at the forefront of modern molecular methodologies, oftenintegrating across wet-lab cell and tissue models, dry-lab computational approaches,and clinical studies. The continuing development and application ofmultiomics methods offer particular challenges and opportunities in the field,not least in the potential for personalized medicine. 
540 |a Creative Commons  |f https://creativecommons.org/licenses/by/4.0/  |2 cc  |4 https://creativecommons.org/licenses/by/4.0/ 
546 |a English 
650 7 |a Research & information: general  |2 bicssc 
653 |a LMNA 
653 |a Emery-Dreifuss muscular dystrophy 
653 |a Omics 
653 |a ALS 
653 |a MND 
653 |a ALS variants 
653 |a genotype-phenotype 
653 |a ALS genes 
653 |a FSHD 
653 |a DUX4 
653 |a transcription 
653 |a muscle 
653 |a regulation 
653 |a spinal muscular atrophy 
653 |a adult patients 
653 |a disease heterogeneity 
653 |a Nusinersen 
653 |a disease modifiers 
653 |a functional outcomes 
653 |a biomarkers 
653 |a epigenetic changes 
653 |a -omics approaches 
653 |a oxidative stress 
653 |a mitochondria dysfunction 
653 |a axonal transport 
653 |a autophagy 
653 |a endocytosis 
653 |a secretion 
653 |a excitotoxicity 
653 |a RNA metabolism 
653 |a Duchenne muscular dystrophy (DMD) 
653 |a exon-skipping therapies 
653 |a next-generation sequencing (NGS) 
653 |a Sanger sequencing 
653 |a multiplex ligation probe amplification (MLPA) 
653 |a multiplex polymerase chain reaction (PCR) 
653 |a comparative genomic hybridization array (CGH) 
653 |a viltolarsen 
653 |a eteplirsen 
653 |a golodirsen 
653 |a rheumatoid arthritis 
653 |a SNP 
653 |a DMARD 
653 |a methotrexate 
653 |a pharmacogenomics 
653 |a Duchenne muscular dystrophy 
653 |a pharmacodynamic biomarkers 
653 |a prednisone 
653 |a deflazacort 
653 |a glucocorticoids 
653 |a corticosteroids 
653 |a safety 
653 |a neuromuscular diseases 
653 |a translational research 
653 |a disease models 
653 |a precision medicine 
653 |a miRNA 
653 |a proteomics 
653 |a calprotectin 
653 |a dystrophy 
653 |a Becker muscular dystrophy 
653 |a dystrophinopathy 
653 |a genotype-phenotype correlations 
653 |a Canadian Neuromuscular Disease Registry 
653 |a reading frame rule 
653 |a dystrophin 
653 |a multiple logistic regression analysis 
653 |a exon skipping therapy 
653 |a Amyotrophic Lateral Sclerosis 
653 |a machine learning 
653 |a genome-wide association studies 
653 |a GWAS 
653 |a genomics 
653 |a ALS pathology 
653 |a gene prioritization 
653 |a AAV 
653 |a genetic neuromuscular disorders 
653 |a gene therapy 
653 |a clinical trials 
653 |a toxicity 
653 |a SMA 
653 |a DMD 
653 |a XLMTM 
653 |a facioscapulohumeral dystrophy 
653 |a TALEN 
653 |a CRISPR-Cas9 
653 |a gene editing 
653 |a polyadenylation 
653 |a D4Z4 
653 |a duchenne muscular dystrophy (DMD) 
653 |a becker muscular dystrophy (BMD) 
653 |a exon skipping 
653 |a skip-equivalent deletions 
653 |a n/a 
856 4 0 |a www.oapen.org  |u https://mdpi.com/books/pdfview/book/4540  |7 0  |z DOAB: download the publication 
856 4 0 |a www.oapen.org  |u https://directory.doabooks.org/handle/20.500.12854/76949  |7 0  |z DOAB: description of the publication